Chenomx Inc. has been awarded two U.S. patents for its Nuclear Magnetic Resonance (NMR)-based mixture analysis algorithms.
First made available to customers in 2001 through Chenomx NMR Suite, Chenomx’s flagship software product, Chenomx’s mixture analysis algorithms allow users to identify and quantify compounds in complex mixtures.
Chenomx NMR Suite has been initially applied in the field of metabolomics, where it has been used to identify and quantify a broad range of metabolites in complex biofluid samples, including blood, urine and cell extracts.
“We are extremely happy to have the innovation and technical accomplishments that make up Chenomx’s technology platform recognized by the U.S. Patent Office,” says Neil Taylor, President and CEO of Chenomx.
The two patents describe the methods that are embodied in Chenomx NMR Suite for creating signatures of metabolites and using these signatures to deconvolve complex NMR spectra. These techniques allow complex, information-rich NMR spectra to be transformed into biologically meaningful metabolic profiles – lists of identified and quantified metabolites.
In recognition of nature of Chenomx’s methods, the U.S.Patent Office awarded Patent Nos. 7181348 and 7491069 to Chenomx Inc. on February 20, 2007 and March 13, 2007, respectively. Chenomx’s technology has been previously awarded two patents in the U.K., Patent Nos. 2390166 and 2410599, issued on August 3, 2005 and September 28, 2005, respectively.